Related Experiment Video

Updated: Jul 28, 2026

Low Molecular Weight Protein Enrichment on Mesoporous Silica Thin Films for Biomarker Discovery
13:00

Low Molecular Weight Protein Enrichment on Mesoporous Silica Thin Films for Biomarker Discovery

Published on: April 17, 2012

[Medium molecular size peptides of blood plasma in diabetes mellitus]

V V Alabovskiĭ, D V Vasilenko, A I Maslov

    Klinicheskaia Laboratornaia Diagnostika
    |July 13, 2005
    PubMed

    Insights

    Medium molecular peptides (MMP) increase in diabetes mellitus (DM), causing intoxication. Diabetic nephropathy onset significantly decreases MMP levels in all diabetes types.

    Area of Science:

    • Biochemistry
    • Endocrinology
    • Nephrology

    Context:

    • Diabetes Mellitus (DM) is a metabolic disorder characterized by hyperglycemia.
    • Endogenous intoxication is a pathological condition resulting from the accumulation of toxic substances within the body.
    • Medium molecular peptides (MMP) are a group of molecules implicated in various physiological and pathological processes.

    Purpose:

    • To investigate the correlation between medium molecular peptide (MMP) levels and the progression of diabetes mellitus (DM).
    • To analyze MMP concentration variations in different types of DM (insulin-dependent vs. insulin-independent) and disease severity.
    • To determine the impact of diabetic nephropathy onset on MMP levels.

    Summary:

    • Elevated medium molecular peptide (MMP) levels in blood plasma are observed in patients with diabetes mellitus (DM), contributing to endogenous intoxication.
    • MMP concentration is higher in compensated, insulin-independent DM without renal involvement compared to insulin-dependent DM, potentially due to specific peptide fractions (1-3 kDa).
    • Aggravated DM, including subcompensation, correlates with increased MMP levels in both DM types. However, the initial stage of diabetic nephropathy leads to a significant reduction in all MMP fractions.

    Impact:

    • This study highlights MMPs as potential biomarkers for monitoring DM progression and complications.
    • Understanding MMP dynamics can inform therapeutic strategies for managing endogenous intoxication in diabetic patients.
    • The findings suggest a potential role for MMPs in the early detection and assessment of diabetic nephropathy.

    More Related Videos

    Extraction of Tissue Antigens for Functional Assays08:32

    Extraction of Tissue Antigens for Functional Assays

    Published on: September 10, 2012

    Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

    Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

    Published on: November 5, 2016

    Related Concept Videos

    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
    Diabetes Mellitus: Introduction01:26

    Diabetes Mellitus: Introduction

    Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
    Type I Diabetes III: Clinical Manifestations01:19

    Type I Diabetes III: Clinical Manifestations

    Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
    Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

    Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

    Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
    Diabetic Nephropathy01:28

    Diabetic Nephropathy

    Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...